Latest Conference Articles

December 8th 2021, 5:40pm

San Antonio Breast Cancer Symposium

Higher Oncotype DX recurrence scores were associated with prolonged persistence to 5 years of endocrine therapy vs lower Oncotype DX recurrence scores in patients with low-risk, estrogen receptor-positive/progesterone receptor–positive breast cancer, according to findings from a retrospective review.

December 8th 2021, 5:02pm

San Antonio Breast Cancer Symposium

Aileen I. Fernandez, PhD, discusses the results of a study examining low HER2 expression in breast cancer.

December 8th 2021, 2:58pm

San Antonio Breast Cancer Symposium

Datopotamab deruxtecan showed highly encouraging and durable efficacy through overall response rates in patients with advanced or metastatic triple-negative breast cancer.

December 7th 2021, 10:48pm

San Antonio Breast Cancer Symposium

The combination of entinostat and exemestane led to a significant improvement in progression-free survival compared with placebo and exemestane in Chinese patients with advanced hormone receptor–positive breast cancer.

December 7th 2021, 10:10pm

San Antonio Breast Cancer Symposium

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab resulted in a statistically significant and clinically meaningful improvement in event-free survival in patients with early-stage triple negative breast cancer.

December 7th 2021, 9:38pm

San Antonio Breast Cancer Symposium

Adding adjuvant palbociclib to standard endocrine therapy did not improve outcomes in patients with stage II to III hormone receptor–positive, HER2-negative early breast cancer.

December 7th 2021, 9:08pm

San Antonio Breast Cancer Symposium

Pembrolizumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival vs chemotherapy alone in patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer who have a PD-L1 combined positive score of 10 or higher.

December 7th 2021, 7:21pm

San Antonio Breast Cancer Symposium

Metformin failed to improve invasive disease-free survival or overall survival when used as adjuvant treatment in patients with early breast cancer, irrespective of estrogen or progesterone receptor status.

December 7th 2021, 2:35pm

San Antonio Breast Cancer Symposium

Patients with primary breast cancer who developed secondary uterine cancer following treatment with tamoxifen may have had disease driven by PI3K-pathway activation.

December 7th 2021, 2:00pm

Patients with hormone receptor–positive, HER2-negative metastatic breast cancer with rising ESR1 mutations previously treated with an aromatase inhibitor plus palbociclib had a doubling of progression-free survival when switched to fulvestrant plus palbociclib before disease progression, according to findings from the phase 3 PADA-1 trial.

December 7th 2021, 2:00pm

San Antonio Breast Cancer Symposium

Genomic alterations identified through multigene sequencing, classified in the I/II tiers of the ESMO Scale of Actionability of Molecular Targets, and paired with matching targeted therapy led to a significant improvement in progression-free survival vs maintenance chemotherapy in patients with HER2-negative metastatic breast cancer.

December 7th 2021, 2:00pm

San Antonio Breast Cancer Symposium

Imaging mass cytometry at the single-cell level showed potential as an immunotherapy response prediction tool in early triple-negative breast cancer.

December 3rd 2021, 2:28pm

ASH Annual Meeting and Exposition

Lisocabtagene maraleucel significantly prolonged event-free survival and progression-free survival and improved complete responses when used in the second-line treatment of patients with relapsed or refractory large B-cell lymphoma.

November 29th 2021, 2:13pm

ASH Annual Meeting and Exposition

Lisocabtagene maraleucel demonstrated durable responses and a favorable safety profile in patients with relapsed/refractory large B-cell lymphoma.

November 23rd 2021, 8:59pm

SITC Meeting

Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.

November 23rd 2021, 8:55pm

SITC Meeting

Kim A. Reiss Binder, MD, discusses the initial results of a phase 1 trial, which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors.

November 19th 2021, 7:59pm

SITC Meeting

Myrto Moutafi, MD, MSc, discusses the results of a study evaluating biomarkers of resistance in non–small cell lung cancer.

November 19th 2021, 7:56pm

SITC Meeting

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

November 19th 2021, 7:51pm

SITC Meeting

Hans Wildiers, MD, medical oncologist, Department of Medical Oncology, full professor, Faculty of Medicine, member, Laboratory of Experimental Oncology, University Hospital Leuven, Leuven, Belgium, discusses the final results of the phase 2b AIPAC trial (NCT02614833) in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

November 19th 2021, 7:48pm

SITC Meeting

Jonathan D. Cheng, MD, discusses advances with immunotherapy-based combinations in oncology.